Navigation Links
Bavarian Nordic A/S - Half Year Interim Report 2009
Date:8/28/2009

KVISTGAARD, Denmark, August 28 /PRNewswire-FirstCall/ -- Today Bavarian Nordic published the company's half-year interim report 2009. The full financial statements are available on the company's website: http://www.bavarian-nordic.com. Below is an extract of the most significant matters in the report as well as events after the balance sheet date.

In the first half of 2009 Bavarian Nordic generated revenue of DKK 33 million and recorded a loss before tax of DKK 188 million. As of 30 June 2009 the Group's net free liquidity was DKK 489 million.

Bavarian Nordic's new prostate cancer vaccine - PROSTVAC(TM) has been further validated and shows blockbuster potential. Bavarian Nordic is progressing the development and Phase III preparations of PROSTVAC(TM):

    - End of phase II meeting with the FDA in Q4, 2009 and expected
      initiation of Phase III in 2010
    - Five ongoing clinical Phase I and II studies in different patient
      populations
    - Preparing the production for Phase III studies
    - Scientific publication of data
    - Ongoing discussions with prospective licensing partners

The U.S. Food and Drug Administration (FDA) has performed a GMP inspection of the IMVAMUNE(R) manufacturing facilities. These GMP inspections occurred at both Bavarian Nordic's Kvistgaard facility and at IDT in May 2009. The management of Bavarian Nordic consider these inspections to be successfully completed, and the corrective actions triggered by the inspections will be implemented within short time, causing no further investments. Bavarian Nordic has an ongoing and positive dialogue with FDA which confirms the expectations to start deliveries of IMVAMUNE(R) under the RFP-3 contract following the satisfactory implementation of the corrective actions. On this background the company expects delive
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
9. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
10. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 30, 2014 Each year in ... require medical attention. In the military, burn injury ... to battlefield medical care. More than 800 service ... Burn wounds heal slowly, remain inflamed and often ... physically debilitating and functionally damaging. While developments in ...
(Date:9/29/2014)... Iraq and Afghanistan, more than 300,000 soldiers have returned ... by exposure to bomb blasts and in particular, ... traumatic brain injury can range from the mild, such ... in memory and cognition. , Since 2007, the ... and complexity of this problem, and has made significant ...
(Date:9/29/2014)... , Sept. 29, 2014 Research ... "Oligonucleotide Synthesis Market by Product & Services, End-User , ... their offering. The global oligonucleotide synthesis ... from $1,070.7 million in 2014, growing at a CAGR ... synthesis market is categorized on the basis of products ...
(Date:9/29/2014)... in food security, emerging diseases and biodiversity loss ... online in Science Express that was ... Arizona College of Agriculture and Life Sciences. , ... nine scientists has reviewed progress in addressing a ... environmental management using approaches that consider evolutionary histories ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3
... Calif., Sept. 29, 2011 Ambry Genetics today ... provide CLIA-approved exome services for applications in clinical ... geneticists and medical directors, these results will allow ... have eluded traditional diagnostic approaches. ...
... 29, 2011 Dr. Barrett Bready, CEO of NABsys, ... Year. Dr. Bready will be honored at a ceremony ... presented by the Providence Business News in partnership with ... Bryant University, Cox Business, Edwards Angell Palmer & Dodge, ...
... system, you probably think about it fighting off a cold. ... immune cells in your brain may contribute to how you ... 10,000 years of using alcohol, and several decades of investigation ... our brain, we are still trying to figure out exactly ...
Cached Biology Technology:Ambry Genetics First to Offer Exome Sequencing Service for Clinical Diagnostics. 2NABsys CEO Barrett Bready Named Rhode Island Innovator of the Year 2Alcohol-related behavior changes -- blame your immune system 2
(Date:9/29/2014)... from the skeleton of a man who lived 2,330 years ... ourselves as humans? A great deal when his DNA profile ... terms found to-date in a region where modern humans ... , The man,s maternal DNA, or ,mitochondrial DNA, was sequenced ... Mitochondrial DNA provided the first evidence that we all come ...
(Date:9/29/2014)... -- NXT-ID, Inc. (Nasdaq: NXTD and ... focused on the growing mobile commerce market, today announced ... the Company,s Vice-President and Chief Financial Officer effective immediately. ... Financial Officer. Mr. Pereira will continue to serve as ... Mr. Miceli, age 56, has extensive hands ...
(Date:9/29/2014)... were able to safely tolerate treatment with cells cultured ... today in the journal Multiple Sclerosis and Related ... its kind, was conducted by researchers at Mount Sinai, ... at several other institutions. , While designed to ... data also suggested that a preparation of cultured cells ...
Breaking Biology News(10 mins):Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3Cells from placentas safe for patients with multiple sclerosis 2
... A team led by the University of Colorado Boulder has been ... Energy to research modifying E. coli to produce biofuels ... take what we have worked on for the past decade to ... CU-Boulder,s Renewable and Sustainable Energy Institute, or RASEI. "In this project, ...
... Ian Bell, PhD, the Louis Block Distinguished Service Professor ... the Kovler Diabetes Center at the University of Chicago, ... 2012 for his pioneering work in understanding the role ... The prize, the world,s largest award for ...
... scientists produce better climate-resistant corn and other food production plants ... what we eat. Kansas State University geneticists and colleagues ... and prioritize the genes in humans, it improved the likelihood ... control quantitate traits in plants, such as how the plants ...
Cached Biology News:CU-led team receives $9.2 million DOE grant to engineer E. coli into biofuels 2University of Chicago's Graeme Bell receives international diabetes prize 2University of Chicago's Graeme Bell receives international diabetes prize 3Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 2Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 3